Lactoferrin as a natural immune modulator

Current Pharmaceutical Design

Volumn 15, Issue 17, 2009, Pages 1956-1973

  Actor, Jeffrey K ^a   Hwang, Shen An ^a   Kruzel, Marian L ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Adaptive immunity; Adjuvant; Immunomodulation; Inflammation; Innate immunity; Lactoferrin; Oxidative stress

Indexed keywords

BCG VACCINE; CASPASE 3; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; L SELECTIN; LACTOFERRIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEGALIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; B LYMPHOCYTE; BACTEREMIA; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; LACTOFERRIN; OXIDATIVE STRESS; RECEPTORS, CELL SURFACE; STAPHYLOCOCCAL INFECTIONS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 68449088241     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788453202     Document Type: Review

References (204)

1. Chodaczek G, Saavedra-Molina A, Bacsi A, Kruzel ML, Sur S, Boldogh I. Iron-mediated dismutation of superoxide anion augments antigen-induced allergic inflammation: Effect of lactoferrin. Postepy Hig Med Dosw (Online) 2007; 61: 268-76.
2. Kruzel ML, Actor JK, Boldogh I, Zimecki M. Lactoferrin in health and disease. Postepy Hig Med Dosw (Online) 2007; 61: 261-7.
3. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J. Lactoferrin structure and functions. Adv Exp Med Biol 2008; 606: 163-94.
4. Baker EN, Baker HM. Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci 2005; 62: 2531-9.
5. Baggiolini M, De Duve C, Masson PL, Heremans JF. Association of lactoferrin with specific granules in rabbit heterophil leukocytes. J Exp Med 1970; 131: 559-70.
6. Lonnerdal B, Iyer S. Lactoferrin: Molecular structure and biological function. Annu Rev Nutr 1995; 15: 93-110.
7. Sanchez L, Calvo M, Brock JH. Biological role of lactoferrin. Arch Dis Child 1992; 67: 657-61.
8. Clare DA, Catignani GL, Swaisgood HE. Biodefense properties of milk: The role of antimicrobial proteins and peptides. Curr Pharm Des 2003; 9: 1239-55.
9. Baveye S, Elass E, Mazurier J, Spik G, Legrand D. Lactoferrin: A multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med 1999; 37: 281-6.
10. Baynes RD, Bezwoda WR. Lactoferrin and the inflammatory response. Adv Exp Med Biol 1994; 357: 133-41.
11. Kruzel ML, Harari Y, Mailman D, Actor JK, Zimecki M. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin Exp Immunol 2002; 130: 25-31.
12. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1992; 1121: 130-6.
13. Tomita M, Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J Dairy Sci 1991; 74: 4137-42.
14. Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br J Exp Pathol 1989; 70: 697-704.
15. Jenssen H, Hancock RE. Antimicrobial properties of lactoferrin. Biochimie 2009; 91(1): 19-29.
16. Farnaud S, Evans RW. Lactoferrin - a multifunctional protein with antimicrobial properties. Mol Immunol 2003; 40: 395-405.
17. Vorland LH. Lactoferrin: A multifunctional glycoprotein. Apmis 1999; 107: 971-81.
18. Ellison RT, 3rd, Giehl TJ. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991; 88: 1080-91.
19. Ward PP, Paz E, Conneely OM. Multifunctional roles of lactoferrin: A critical overview. Cell Mol Life Sci 2005; 62: 2540-8.
20. Orsi N. The antimicrobial activity of lactoferrin: Current status and perspectives. Biometals 2004; 17: 189-96.
21. Valenti P, Antonini G. Lactoferrin: An important host defence against microbial and viral attack. Cell Mol Life Sci 2005; 62: 2576-87.
22. Weinberg ED. Antibiotic properties and applications of lactoferrin. Curr Pharm Des 2007; 13: 801-11.
23. Amati L, Caradonna L, Leandro G, Magrone T, Minenna M, Faleo G, et al. Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: Attempts at neutralizing endotoxin-mediated effects. Curr Pharm Des 2003; 9: 1937-45.
24. Adamik B, Zimecki M, Wlaszczyk A, Kubler A. Immunological status of septic and trauma patients. I. High tumor necrosis factor alpha serum levels in septic and trauma patients are not responsible for increased mortality; a prognostic value of serum interleukin 6. Arch Immunol Ther Exp (Warsz) 1997; 45: 169-75.
25. Adamik B, Zimecki M, Wlaszczyk A, Kubler A. Immunological status of septic and trauma patients. II. Proliferative response and production of interleukin 6 and tumor necrosis factor alpha by peripheral blood mononuclear cells from septic survivor, nonsurvivor and trauma patients: a correlation with the survival rate. Arch Immunol Ther Exp (Warsz) 1997; 45: 277-84.
26. Puddu P, Borghi P, Gessani S, Valenti P, Belardelli F, Seganti L. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int J Biochem Cell Biol 1998; 30: 1055-62.
27. van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK. Antiviral activities of lactoferrin. Antiviral Res 2001; 52: 225- 39.
28. Giansanti F, Rossi P, Massucci MT, Botti D, Antonini G, Valenti P, Seganti L. Antiviral activity of ovotransferrin discloses an evolutionary strategy for the defensive activities of lactoferrin. Biochem Cell Biol 2002; 80: 125-30.
29. Jenssen H. Anti herpes simplex virus activity of lactoferrin/ lactoferricin - an example of antiviral activity of antimicrobial protein/peptide. Cell Mol Life Sci 2005; 62: 3002-13.
30. Seganti L, Di Biase AM, Marchetti M, Pietrantoni A, Tinari A, Superti F. Antiviral activity of lactoferrin towards naked viruses. Biometals 2004; 17: 295-9.
31. Gifford JL, Hunter HN, Vogel HJ. Lactoferricin: A lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 2005; 62: 2588-98.
32. Florisa R, Recio I, Berkhout B, Visser S. Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr Pharm Des 2003; 9: 1257-75.
33. Turchany JM, Aley SB, Gillin FD. Giardicidal activity of lactoferrin and N-terminal peptides. Infect Immun 1995; 63: 4550-2.
34. Dzitko K, Dziadek B, Dziadek J, Dlugonska H. Toxoplasma gondii: inhibition of the intracellular growth by human lactoferrin. Pol J Microbiol 2007; 56: 25-32.
35. Tanaka T, Omata Y, Saito A, Shimazaki K, Igarashi I, Suzuki N. Growth inhibitory effects of bovine lactoferrin to Toxoplasma gondii parasites in murine somatic cells. J Vet Med Sci 1996; 58: 61-5.
36. Cirioni O, Giacometti A, Barchiesi F, Scalise G. Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J Antimicrob Chemother 2000; 46: 577-82.
37. Okamoto T, Tanida T, Wei B, Ueta E, Yamamoto T, Osaki T. Regulation of fungal infection by a combination of amphotericin B and peptide 2, a lactoferrin peptide that activates neutrophils. Clin Diagn Lab Immunol 2004; 11: 1111-9.
38. Viejo-Diaz M, Andres MT, Fierro JF. Modulation of in vitro fungicidal activity of human lactoferrin against Candida albicans by extracellular cation concentration and target cell metabolic activity. Antimicrob Agents Chemother 2004; 48: 1242-8.
39. Ueta E, Tanida T, Osaki T. A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. J Pept Res 2001; 57: 240-9.
40. Xu YY, Samaranayake YH, Samaranayake LP, Nikawa H. In vitro susceptibility of Candida species to lactoferrin. Med Mycol 1999; 37: 35-41.
41. Lupetti A, van Dissel JT, Brouwer CP, Nibbering PH. Human antimicrobial peptides' antifungal activity against Aspergillus fumigatus. Eur J Clin Microbiol Infect Dis 2008.
42. Drobni P, Naslund J, Evander M. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res 2004; 64: 63- 8.
43. Ochoa TJ, Noguera-Obenza M, Cleary TG. Lactoferrin blocks the initial host cell attachment mechanism of Enteropathogenic E. coli (EPEC). Adv Exp Med Biol 2004; 554: 463-6.
44. Kawasaki Y, Tazume S, Shimizu K, Matsuzawa H, Dosako S, Isoda H, et al. Inhibitory effects of bovine lactoferrin on the adherence of enterotoxigenic Escherichia coli to host cells. Biosci Biotechnol Biochem 2000; 64: 348-54.
45. Kruzel ML, Bacsi A, Choudhury B, Sur S, Boldogh I. Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma. Immunology 2006; 119: 159-66.
46. Zimecki M, Miedzybrodzki R, Mazurier J, Spik G. Regulatory effects of lactoferrin and lipopolysaccharide on LFA-1 expression on human peripheral blood mononuclear cells. Arch Immunol Ther Exp (Warsz) 1999; 47: 257-64.
47. Zimecki M, Kocieba M, Kruzel M. Immunoregulatory activities of lactoferrin in the delayed type hypersensitivity in mice are mediated by a receptor with affinity to mannose. Immunobiology 2002; 205: 120-31
48. Zimecki M, Mazurier J, Spik G, Kapp JA. Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology 1995; 86: 122-7.
49. Zimecki M, Mazurier J, Machnicki M, Wieczorek Z, Montreuil J, Spik G. Immunostimulatory activity of lactotransferrin and maturation of CD4- CD8- murine thymocytes. Immunol Lett 1991; 30: 119-23.
50. Actor JK, Hwang SA, Olsen M, Zimecki M, Hunter RL, Jr., Kruzel ML. Lactoferrin immunomodulation of DTH response in mice. Int Immunopharmacol 2002; 2: 475-86.
51. Zimecki M, Kapp J, Machnicki M, Zagulski T, Wlaszczyk A, Kubler A, et al. Lactoferrin. Its role in maturation and function of cells of the immune system and protection against shock in mice. Adv Exp Med Biol 1998; 443: 331-6.
52. Gutteridge JM. Hydroxyl radicals, iron, oxidative stress, and neurodegeneration. Ann N Y Acad Sci 1994; 738: 201-13.
53. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 1991; 24: 203-14.
54. Touyz RM. Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep 2000; 2: 98-105.
55. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 1996; 48: 1-19.
56. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathol 1999; 9: 133-46.
57. Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol 1994; 7: 548-58.
58. Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996; 36: 83-106.
59. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689-95.
60. Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury. Cell Mol Neurobiol 1998; 18: 667-82.
61. Kovacic P, Jacintho JD. Mechanisms of carcinogenesis: Focus on oxidative stress and electron transfer. Curr Med Chem 2001; 8: 773-96.
62. Parodi PW. A role for milk proteins and their peptides in cancer prevention. Curr Pharm Des 2007; 13: 813-28.
63. Bowler RP, Crapo JD. Oxidative stress in allergic respiratory diseases. J Allergy Clin Immunol 2002; 110: 349-56.
64. Haber F, Weiss J. On the catalysis of hydroperoxide. Naturwissenschaften 1932; 20: 948-50.
65. Mulder AM, Connellan PA, Oliver CJ, Morris CA, Stevenson LM. Bovine lactoferrin supplementation supports immune and antioxidant status in healthy human males. Nutr Res 2008; 28: 583-9.
66. Gutteberg TJ, Rokke O, Andersen O, Jorgensen T. Early fall of circulating iron and rapid rise of lactoferrin in septicemia and endotoxemia: An early defence mechanism. Scand J Infect Dis 1989; 21: 709-15.
67. Exline MC, Crouser ED. Mitochondrial mechanisms of sepsis-induced organ failure. Front Biosci 2008; 13: 5030-41.
68. Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF. Gram-negative endotoxin: An extraordinary lipid with profound effects on eukaryotic signal transduction. Faseb J 1991; 5: 2652-60.
69. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995; 13: 437-57
70. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 1601-8.
71. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 1992; 216: 117-34.
72. Deitch EA. Role of bacterial translocation in necrotizing enterocolitis. Acta Paediatr Suppl 1994; 396: 33-6.
73. DeMaria E, Dalton J. Bacterial translocation and the release of endotoxin and cytokines following trauma. In Cytokines in trauma and hemorrhage. Edited by Sugerman HJ, DeMaria EJ: Chapman & Hall; 1997: 43-61. Medical intelligence unit
74. Nadler EP, Upperman JS, Dickinson EC, Ford HR. Nitric oxide and intestinal barrier failure. Semin Pediatr Surg 1999; 8: 148-54.
75. Kruzel ML, Harari Y, Chen CY, Castro GA. The gut. A key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Adv Exp Med Biol 1998; 443: 167-73.
76. Zimecki M, Spiegel K, Wlaszczyk A, Kubler A, Kruzel ML. Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells. Arch Immunol Ther Exp (Warsz) 1999; 47: 113-8.
77. Kruzel ML, Harari Y, Chen CY, Castro GA. Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice. Inflammation 2000; 24: 33-44.
78. Kruzel M, Zagulski T, Zimecki M. Lactoferrin and insult-induced metabolic imbalance. In 4th International Congress on Lactoferrin; Sapporo, Japan: Excerpta Medica International Congress Series: 1999.
79. Kruzel M. Role of lactoferrin in development of Systemic Inflammatory Response Syndrome. In 2nd International Congress on Intensive Care; Wroclaw, Poland: Infection and Immunity: 1998.
80. Zagulski T, Lipinski P, Zagulska A, Jarzabek Z. Antibacterial system generated by lactoferrin in mice in vivo is primarily a killing system. Int J Exp Pathol 1998; 79: 117-23.
81. Berlyn MK. Linkage map of Escherichia coli K-12, edition 10: The traditional map. Microbiol Mol Biol Rev 1998; 62: 814-984.
82. Tan XX, Actor JK, Chen Y. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: Proof of principle using mouse intraperitoneal infection. Antimicrob Agents Chemother 2005; 49: 3203-7.
83. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol 2005; 3: 948-58.
84. Holtfreter S, Broker BM. Staphylococcal superantigens: Do they play a role in sepsis? Arch Immunol Ther Exp (Warsz) 2005; 53: 13-27.
85. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: An update. Annu Rev Microbiol 2001; 55: 77-104.
86. Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin: A modulator of immune and inflammatory responses. Cell Mol Life Sci 2005; 62: 2549-59.
87. Damiens E, Mazurier J, el Yazidi I, Masson M, Duthille I, Spik G, et al. Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells. Biochim Biophys Acta 1998; 1402: 277-87.
88. Shau H, Kim A, Golub SH. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J Leukoc Biol 1992; 51: 343-9.
89. Miyauchi H, Hashimoto S, Nakajima M, Shinoda I, Fukuwatari Y, Hayasawa H. Bovine lactoferrin stimulates the phagocytic activity of human neutrophils: Identification of its active domain. Cell Immunol 1998; 187: 34-7.
90. Kawai K, Shimazaki K, Higuchi H, Nagahata H. Antibacterial activity of bovine lactoferrin hydrolysate against mastitis pathogens and its effect on superoxide production of bovine neutrophils. Zoonoses Public Health 2007; 54: 160-4.
91. Ward PP, Mendoza-Meneses M, Park PW, Conneely OM. Stimulus-dependent impairment of the neutrophil oxidative burst response in lactoferrin-deficient mice. Am J Pathol 2008; 172: 1019- 29.
92. Longhi C, Conte MP, Penta M, Cossu A, Antonini G, Superti F, et al. Lactoferricin influences early events of Listeria monocytogenes infection in THP-1 human macrophages. J Med Microbiol 2004; 53: 87-91
93. Wakabayashi H, Takakura N, Teraguchi S, Tamura Y. Lactoferrin feeding augments peritoneal macrophage activities in mice intraperitoneally injected with inactivated Candida albicans. Microbiol Immunol 2003; 47: 37-43.
94. Sorimachi K, Akimoto K, Hattori Y, Ieiri T, Niwa A. Activation of macrophages by lactoferrin: Secretion of TNF-alpha, IL-8 and NO. Biochem Mol Biol Int 1997; 43: 79-87.
95. Na YJ, Han SB, Kang JS, Yoon YD, Park SK, Kim HM, et al. Lactoferrin works as a new LPS-binding protein in inflammatory activation of macrophages. Int Immunopharmacol 2004; 4: 1187- 99.
96. Puddu P, Carollo MG, Belardelli F, Valenti P, Gessani S. Role of endogenous interferon and LPS in the immunomodulatory effects of bovine lactoferrin in murine peritoneal macrophages. J Leukoc Biol 2007; 82: 347-53.
97. Suzuki YA, Lopez V, Lonnerdal B. Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 2005; 62: 2560-75.
98. Mincheva-Nilsson L, Hammarstrom S, Hammarstrom ML. Activated human gamma delta T lymphocytes express functional lactoferrin receptors. Scand J Immunol 1997; 46: 609-18.
99. Hammarstrom ML, Mincheva-Nilsson L, Hammarstrom S. Functional lactoferrin receptors on activated human lymphocytes. Adv Exp Med Biol 1995; 371A: 47-53.
100. Birgens HS. The monocytic receptor for lactoferrin and its involvement in lactoferrin-mediated iron transport. Adv Exp Med Biol 1994; 357: 99-109.
101. Iyer S, Lonnerdal B. Lactoferrin, lactoferrin receptors and iron metabolism. Eur J Clin Nutr 1993; 47: 232-41.
102. Groot F, Geijtenbeek TB, Sanders RW, Baldwin CE, Sanchez-Hernandez M, Floris R, et al. Lactoferrin prevents dendritic cellmediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN - gp120 interaction. J Virol 2005; 79: 3009- 15.
103. Zimecki M, Wlaszczyk A, Wojciechowski R, Dawiskiba J, Kruzel M. Lactoferrin regulates the immune responses in post-surgical patients. Arch Immunol Ther Exp (Warsz) 2001; 49: 325-33.
104. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol 1993; 74: 433-9.
105. Zimecki M, Dawiskiba J, Zawirska B, Krawczyk Z, Kruzel M. Bovine lactoferrin decreases histopathological changes in the liver and regulates cytokine production by splenocytes of obstructive jaundiced rats. Inflamm Res 2003; 52: 305-10.
106. Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 2002; 220: 83-95.
107. Wakabayashi H, Kurokawa M, Shin K, Teraguchi S, Tamura Y, Shiraki K. Oral lactoferrin prevents body weight loss and increases cytokine responses during herpes simplex virus type 1 infection of mice. Biosci Biotechnol Biochem 2004; 68: 537-44.
108. Wakabayashi H, Takakura N, Yamauchi K, Tamura Y. Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin Vaccine Immunol 2006; 13: 239-45.
109. Teraguchi S, Wakabayashi H, Kuwata H, Yamauchi K, Tamura Y. Protection against infections by oral lactoferrin: Evaluation in animal models. Biometals 2004; 17: 231-4.
110. Hwang SA, Wilk KM, Bangale YA, Kruzel ML, Actor JK. Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes. Med Microbiol Immunol 2007; 196: 171-80.
111. Wilk KM, Hwang SA, Actor JK. Lactoferrin modulation of antigen-presenting-cell response to BCG infection. Postepy Hig Med Dosw (Online) 2007; 61: 277-82.
112. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-46.
113. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-76
114. Puddu P, Valenti P, Gessani S. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie 2008.
115. Roseanu A, Chelu F, Trif M, Motas C, Brock JH. Inhibition of binding of lactoferrin to the human promonocyte cell line THP-1 by heparin: The role of cell surface sulphated molecules. Biochim Biophys Acta 2000; 1475: 35-8.
116. Britigan BE, Serody JS, Hayek MB, Charniga LM, Cohen MS. Uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical and protects them from membrane autoperoxidation. J Immunol 1991; 147: 4271-7.
117. Tanida T, Rao F, Hamada T, Ueta E, Osaki T. Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor. Infect Immun 2001; 69: 3883-90.
118. Zimecki M, Machnicki M. Lactoferrin inhibits the effector phase of the delayed type hypersensitivity to sheep erythrocytes and inflammatory reactions to M. bovis (BCG). Arch Immunol Ther Exp (Warsz) 1994; 42: 171-7.
119. Hwang SA, Kruzel ML, Actor JK. Influence of bovine lactoferrin on expression of presentation molecules on BCG-infected bone marrow derived macrophages. Biochimie 2009; 91: 76-85.
120. Curran CS, Demick KP, Mansfield JM. Lactoferrin activates macrophages via TLR4-dependent and -independent signaling pathways. Cell Immunol 2006; 242: 23-30.
121. Bhatia S, Edidin M, Almo SC, Nathenson SG. B7-1 and B7-2: Similar costimulatory ligands with different biochemical, oligomeric and signaling properties. Immunol Lett 2006; 104: 70-5.
122. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004; 21: 401-13.
123. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A 1993; 90: 10188-92.
124. Schmitt E, Hoehn P, Huels C, Goedert S, Palm N, Rude E, et al. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur J Immunol 1994; 24: 793-8.
125. Murphy EE, Terres G, Macatonia SE, Hsieh CS, Mattson J, Lanier L, et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994; 180: 223-31.
126. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16: 495-521
127. Iigo M, Shimamura M, Matsuda E, Fujita K, Nomoto H, Satoh J, et al. Orally administered bovine lactoferrin induces caspase-1 and interleukin-18 in the mouse intestinal mucosa: A possible explanation for inhibition of carcinogenesis and metastasis. Cytokine 2004; 25: 36-44.
128. Reddy P. Interleukin-18: Recent advances. Curr Opin Hematol 2004; 11: 405-10.
129. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: Master switches of inflammation. Cell Death Differ 2007; 14: 10-22.
130. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2: 933-44.
131. Ahmadzadeh M, Farber DL. Functional plasticity of an antigen-specific memory CD4 T cell population. Proc Natl Acad Sci U S A 2002; 99: 11802-7.
132. Radhakrishnan S, Wiehagen KR, Pulko V, Van Keulen V, Faubion WA, Knutson KL, et al. Induction of a Th1 response from Th2-polarized T cells by activated Pendritic cells: Dependence on TCR: peptide-MHC interaction, ICAM-1, IL-12, and IFN-gamma. J Immunol 2007; 178: 3583-92.
133. Saidi H, Eslahpazir J, Carbonneil C, Carthagena L, Requena M, Nassreddine N, et al. Differential modulation of human lactoferrin activity against both R5 and X4-HIV-1 adsorption on epithelial cells and dendritic cells by natural antibodies. J Immunol 2006; 177: 5540-9.
134. Cumberbatch M, Dearman RJ, Uribe-Luna S, Headon DR, Ward PP, Conneely OM, et al. Regulation of epidermal Langerhans cell migration by lactoferrin. Immunology 2000; 100: 21-8.
135. Cumberbatch M, Bhushan M, Dearman RJ, Kimber I, Griffiths CE. IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: Regulation by lactoferrin. Clin Exp Immunol 2003; 132: 352-9.
136. Griffiths CE, Cumberbatch M, Tucker SC, Dearman RJ, Andrew S, Headon DR, et al. Exogenous topical lactoferrin inhibits allergeninduced Langerhans cell migration and cutaneous inflammation in humans. Br J Dermatol 2001; 144: 715-25.
137. Kimber I, Cumberbatch M, Dearman RJ, Headon DR, Bhushan M, Griffiths CE. Lactoferrin: Influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation. Biochem Cell Biol 2002; 80: 103-7.
138. Mikkelsen TL, Bakman S, Sorensen ES, Barkholt V, Frokiaer H. Sialic acid-containing milk proteins show differential immuno-modulatory activities independent of sialic acid. J Agric Food Chem 2005; 53: 7673-80.
139. Toebak MJ, de Rooij J, Moed H, Stoof TJ, von Blomberg BM, Bruynzeel DP, et al. Differential suppression of dendritic cell cytokine production by anti-inflammatory drugs. Br J Dermatol 2008; 158: 225-33.
140. Spadaro M, Caorsi C, Ceruti P, Varadhachary A, Forni G, Pericle F, et al. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. Faseb J 2008.
141. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: How does the immune system decide to mount a helper T-cell response? Immunology 2008; 123: 326-38.
142. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15: 297-322.
143. Sanders VM. Epigenetic regulation of Th1 and Th2 cell development. Brain Behav Immun 2006; 20: 317-24.
144. Tanaka T, Morita H, Yoo YC, Kim WS, Kumura H, Shimazaki K. Detection of bovine lactoferrin binding protein on Jurkat human lymphoblastic T cell line. J Vet Med Sci 2004; 66: 865-9.
145. Legrand D, van Berkel PH, Salmon V, van Veen HA, Slomianny MC, Nuijens JH, et al. The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells. Biochem J 1997; 327 (Pt 3): 841-6.
146. Bi BY, Liu JL, Legrand D, Roche AC, Capron M, Spik G, et al. Internalization of human lactoferrin by the Jurkat human lymphoblastic T-cell line. Eur J Cell Biol 1996; 69: 288-96.
147. Dhennin-Duthille I, Masson M, Damiens E, Fillebeen C, Spik G, Mazurier J. Lactoferrin upregulates the expression of CD4 antigen through the stimulation of the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. J Cell Biochem 2000; 79: 583-93.
148. Frydecka I, Zimecki M, Bocko D, Kosmaczewska A, Teodorowska R, Ciszak L, et al. Lactoferrin-induced up-regulation of zeta (zeta) chain expression in peripheral blood T lymphocytes from cervical cancer patients. Anticancer Res 2002; 22: 1897-901.
149. Zimecki M, Stepniak D, Szynol A, Kruzel ML. Lactoferrin regulates proliferative response of human peripheral blood mononuclear cells to phytohemagglutinin and mixed lymphocyte reaction. Arch Immunol Ther Exp (Warsz) 2001; 49: 147-54.
150. Kobayashi S, Sato R, Inanami O, Yamamori T, Yamato O, Maede Y, et al. Reduction of concanavalin A-induced expression of interferon-gamma by bovine lactoferrin in feline peripheral blood mononuclear cells. Vet Immunol Immunopathol 2005; 105: 75-84.
151. Moed H, Stoof TJ, Boorsma DM, von Blomberg BM, Gibbs S, Bruynzeel DP, et al. Identification of anti-inflammatory drugs according to their capacity to suppress type-1 and type-2 T cell profiles. Clin Exp Allergy 2004; 34: 1868-75.
152. Kocieba M, Zimecki M, Kruzel M, Actor J. The adjuvant activity of lactoferrin in the generation of DTH to ovalbumin can be inhibited by bovine serum albumin bearing alpha-D-mannopyranosyl residues. Cell Mol Biol Lett 2002; 7: 1131-6.
153. Zimecki M, Kruzel ML. Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice. Immunol Lett 2000; 74: 183-8.
154. Artym J, Zimecki M, Kruzel ML. Reconstitution of the cellular immune response by lactoferrin in cyclophosphamide-treated mice is correlated with renewal of T cell compartment. Immunobiology 2003; 207: 197-205
155. Artym J, Zimecki M, Paprocka M, Kruzel ML. Orally administered lactoferrin restores humoral immune response in immunocom-promised mice. Immunol Lett 2003; 89: 9-15.
156. Artym J, Zimecki M, Kuryszko J, Kruzel ML. Lactoferrin accelerates reconstitution of the humoral and cellular immune response during chemotherapy-induced immunosuppression and bone marrow transplant in mice. Stem Cells Dev 2005; 14: 548-55.
157. Kruzel M, Artym J, Chodaczek G, Kocieba M, Kochanowska I, Kruzel T, et al. Effects of lactoferrin on stress-related immune dysfunctions in mice and humans. 4th International Whey Conference: Chicago, IL 2005; 121-32.
158. Wang WP, Iigo M, Sato J, Sekine K, Adachi I, Tsuda H. Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Jpn J Cancer Res 2000; 91: 1022-7.
159. Sfeir RM, Dubarry M, Boyaka PN, Rautureau M, Tome D. The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice. J Nutr 2004; 134: 403-9.
160. Li KJ, Lu MC, Hsieh SC, Wu CH, Yu HS, Tsai CY, et al. Release of surface-expressed lactoferrin from polymorphonuclear neutrophils after contact with CD4+ T cells and its modulation on Th1/Th2 cytokine production. J Leukoc Biol 2006; 80: 350-8.
161. Fischer R, Debbabi H, Dubarry M, Boyaka P, Tome D. Regulation of physiological and pathological Th1 and Th2 responses by lactoferrin. Biochem Cell Biol 2006; 84: 303-11.
162. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989; 46: 111-47.
163. Zimecki M, Mazurier J, Spik G, Kapp JA. Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. Arch Immunol Ther Exp (Warsz) 1996; 44: 51-6.
164. Takakura N, Wakabayashi H, Yamauchi K, Takase M. Influences of orally administered lactoferrin on IFN-gamma and IL-10 production by intestinal intraepithelial lymphocytes and mesenteric lymph-node cells. Biochem Cell Biol 2006; 84: 363-8.
165. Guillen C, McInnes IB, Vaughan DM, Kommajosyula S, Van Berkel PH, Leung BP, et al. Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. J Immunol 2002; 168: 3950-7.
166. Hwang SA, Kruzel ML, Actor JK. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. Int Immunopharmacol 2005; 5: 591-9.
167. Hwang SA, Wilk KM, Budnicka M, Olsen M, Bangale YA, Hunter RL, et al. Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis. Vaccine 2007; 25: 6730-43.
168. Debbabi H, Dubarry M, Rautureau M, Tome D. Bovine lactoferrin induces both mucosal and systemic immune response in mice. J Dairy Res 1998; 65: 283-293.
169. Artym J, Zimecki M, Kruzel ML. Effect of lactoferrin on the methotrexate-induced suppression of the cellular and humoral immune response in mice. Anticancer Res 2004; 24: 3831-6.
170. Choi BK, Actor JK, Rios S, d'Anjou M, Stadheim TA, Warburton S, et al. Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: Effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response. Glycoconj J 2008; 25: 581-93.
171. Kumari J, Sahoo PK. Dietary immunostimulants influence specific immune response and resistance of healthy and immunocompromised Asian catfish Clarias batrachus to Aeromonas hydrophila infection. Dis Aquat Organ 2006; 70: 63-70.
172. Kamilya D, Maiti TK, Joardar SN, Mal BC. Adjuvant effect of mushroom glucan and bovine lactoferrin upon Aeromonas hydrophila vaccination in catla, Catla catla (Hamilton). J Fish Dis 2006; 29: 331-7.
173. Chodaczek G, Zimecki M, Lukasiewicz J, Lugowski C. A complex of lactoferrin with monophosphoryl lipid A is an efficient adjuvant of the humoral and cellular immune response in mice. Med Microbiol Immunol 2006; 195: 207-16.
174. Chodaczek G, Zimecki M, Lukasiewicz J, Lugowski C. Lactoferrin-monophosphoryl lipid a complex enhances immunity of mice to Plesiomonas shigelloides CNCTC 138/92. Acta Biochim Pol 2008; 55: 91-6.
175. Thotathil Z, Jameson MB. Early experience with novel immunomodulators for cancer treatment. Expert Opin Investig Drugs 2007; 16: 1391-403.
176. Lin TY, Chu C, Chiu CH. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J Infect Dis 2002; 186: 1161-4.
177. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2004; 26: 473-503.
178. Portielje JE, Kruit WH, Eerenberg AJ, Schuler M, Sparreboom A, Lamers CH, et al. Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: Implications for the use of IL-12 as vaccine adjuvant. Cancer Immunol Immunother 2005; 54: 37-43
179. Stewart-Tull DE, Bleakley CR, Galloway TS. Characteristics of Vibrio cholerae proteinases: Potential, candidate vaccine antigens. Vaccine 2004; 22: 3026-34.
180. Cox TM, Mazurier J, Spik G, Montreuil J, Peters TJ. Iron binding proteins and influx of iron across the duodenal brush border. Evidence for specific lactotransferrin receptors in the human intestine. Biochim Biophys Acta 1979; 588: 120-8.
181. Lopez V, Suzuki YA, Lonnerdal B. Ontogenic changes in lactoferrin receptor and DMT1 in mouse small intestine: Implications for iron absorption during early life. Biochem Cell Biol 2006; 84: 337- 44.
182. Van Snick JL, Masson PL. The binding of human lactoferrin to mouse peritoneal cells. J Exp Med 1976; 144: 1568-80.
183. Legrand D, Elass E, Carpentier M, Mazurier J. Interactions of lactoferrin with cells involved in immune function. Biochem Cell Biol 2006; 84: 282-90.
184. Mazurier J, Montreuil J, Spik G. Visualization of lactotransferrin brush-border receptors by ligand-blotting. Biochim Biophys Acta 1985; 821: 453-60.
185. Leveugle B, Mazurier J, Legrand D, Mazurier C, Montreuil J, Spik G. Lactotransferrin binding to its platelet receptor inhibits platelet aggregation. Eur J Biochem 1993; 213: 1205-11.
186. Grey A, Banovic T, Zhu Q, Watson M, Callon K, Palmano K, et al. The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol 2004; 18: 2268-78.
187. Mazurier J, Legrand D, Hu WL, Montreuil J, Spik G. Expression of human lactotransferrin receptors in phytohemagglutinin-stimulated human peripheral blood lymphocytes. Isolation of the receptors by antiligand-affinity chromatography. Eur J Biochem 1989; 179: 481- 7.
188. Birgens HS, Hansen NE, Karle H, Kristensen LO. Receptor binding of lactoferrin by human monocytes. Br J Haematol 1983; 54: 383-91.
189. Bennett RM, Davis J. Lactoferrin binding to human peripheral blood cells: An interaction with a B-enriched population of lymphocytes and a subpopulation of adherent mononuclear cells. J Immunol 1981; 127: 1211-6.
190. van Snick JL, Markowetz B, Masson PL. The ingestion and digestion of human lactoferrin by mouse peritoneal macrophages and the transfer of its iron into ferritin. J Exp Med 1977; 146: 817-27.
191. Huang RQ, Ke WL, Qu YH, Zhu JH, Pei YY, Jiang C. Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. J Biomed Sci 2007; 14: 121-8.
192. Fillebeen C, Descamps L, Dehouck MP, Fenart L, Benaissa M, Spik G, et al. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J Biol Chem 1999; 274: 7011-7.
193. McAbee DD, Nowatzke W, Oehler C, Sitaram M, Sbaschnig E, Opferman JT, et al. Endocytosis and degradation of bovine apo- and holo-lactoferrin by isolated rat hepatocytes are mediated by recycling calcium-dependent binding sites. Biochemistry 1993; 32: 13749-60.
194. Lopez V, Kelleher SL, Lonnerdal B. Lactoferrin receptor mediates apo- but not holo-lactoferrin internalization via clathrin-mediated endocytosis in trophoblasts. Biochem J 2008; 411: 271-8.
195. Ammendolia MG, Marchetti M, Superti F. Bovine lactoferrin prevents the entry and intercellular spread of herpes simplex virus type 1 in Green Monkey Kidney cells. Antiviral Res 2007; 76: 252-62.
196. Marchetti M, Trybala E, Superti F, Johansson M, Bergstrom T. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology 2004; 318: 405-13.
197. Elass-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M, Tobias PS, et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 1998; 66: 486-91.
198. Baveye S, Elass E, Fernig DG, Blanquart C, Mazurier J, Legrand D. Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex. Infect Immun 2000; 68: 6519-25.
199. Britigan BE, Lewis TS, Waldschmidt M, McCormick ML, Krieg AM. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J Immunol 2001; 167: 2921-8.
200. Mulligan P, White NR, Monteleone G, Wang P, Wilson JW, Ohtsuka Y, et al. Breast milk lactoferrin regulates gene expression by binding bacterial DNA CpG motifs but not genomic DNA promoters in model intestinal cells. Pediatr Res 2006; 59: 656-61.
201. Choi BK, Actor JK, Rios S, d'Anjou M, Stadheim TA, Warburton S, et al. Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: Effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response. Glycoconj J 2008.
202. Spik G, Coddeville B, Mazurier J, Bourne Y, Cambillaut C, Montreuil J. Primary and three-dimensional structure of lactotransferrin (lactoferrin) glycans. Adv Exp Med Biol 1994; 357: 21-32.
203. Elass E, Masson M, Mazurier J, Legrand D. Lactoferrin inhibits the lipopolysaccharide-induced expression and proteoglycan-binding ability of interleukin-8 in human endothelial cells. Infect Immun 2002; 70: 1860-6.
204. Boldogh I, Roy G, Lee MS, Bacsi A, Hazra TK, Bhakat KK, et al. Reduced DNA double strand breaks in chlorambucil resistant cells are related to high DNA-PKcs activity and low oxidative stress. Toxicology 2003; 193: 137-52.